• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

Evaluation of Drug Utilization in Cardiovascular Disease: A Prospective Analysis

    Deepty Arora, Kirti Vishwakarma, Mukesh Sharma, Navpreet Kaur

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 3586-3591

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Cardiovascular disease (CVD) is the major reason of mortality among noncommunicable diseases (NCDs), constituting 26% in India. The present study was conducted to evaluate drug utilization in cardiovascular disease.
Material and methods: The prospective observational study was conducted for a period of 6 months to evaluate drug utilization in cardiovascular disease. The study included a total of 600 patients admitted to intensive coronary care unit. All the medical prescriptions were collected and the data was used to analyze the prescription pattern by prescribing indicators and individual drug use by DDD measure. The data was collected and analyzed for counts and percentages. The mean and standard deviation was computed for continuous variables.
Results: Of the total 600 records, males were 60% and females were 40%. Ischemic Heart Disease (31.66%) and Hypertension (30.25%) were the most common cardiovascular diseases in the study population. Clopidogrel and Isosorbide dinitrate were most commonly prescribed Cardiovascular Drugs. It was found that Clopidogrel (51.80%), atorvastatin (48.95%), Isosorbide dinitrate (50.76%), were highly used. DDD was highest of Enalapril maleate i.e. 4.43. The average drugs per prescription during hospitalization was 4.15. Percentage number of drugs Prescribed by generic names was 71.5%. Percentage of Drugs Prescribed From National Essential Drug List was 88%.
Conclusion: The present study concluded that the most commonly prescribed medications are Clopidogrel, Isosorbide Dinitrate. Percentage of drugs prescribed by Generic name should be improved. The percentage of drugs prescribed form national Essential Drugs List was satisfactory but still have to be improved.
Keywords:
    Drug Utilization Cardiovascular disease Prescription
  • PDF (217 K)
  • XML
(2022). Evaluation of Drug Utilization in Cardiovascular Disease: A Prospective Analysis. European Journal of Molecular & Clinical Medicine, 9(7), 3586-3591.
Deepty Arora, Kirti Vishwakarma, Mukesh Sharma, Navpreet Kaur. "Evaluation of Drug Utilization in Cardiovascular Disease: A Prospective Analysis". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 3586-3591.
(2022). 'Evaluation of Drug Utilization in Cardiovascular Disease: A Prospective Analysis', European Journal of Molecular & Clinical Medicine, 9(7), pp. 3586-3591.
Evaluation of Drug Utilization in Cardiovascular Disease: A Prospective Analysis. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 3586-3591.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 32
  • PDF Download: 65
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus